Zhiqiang Meng, MD, PhD

Biography:
Dr. Meng graduated from Shanghai Medical University, received his MD in 1999 and PhD in 2004; he was trained in the M.D. Anderson Cancer Center (Houston, USA). He was appointed Adjunct Professor of M.D. Anderson Cancer Center in 2012. He currently serves as Director of the Minimally Invasive Therapy Center and Integrative Oncology, Fudan University Shanghai Cancer Center.

Academic position:
Chairman, Committee of Experts of Ablation Therapy, Chinese Society of Clinical Oncology(CSCO);
Chairman, Committee of Minimally Invasive Therapy in Oncology of Shanghai Anti-cancer Association (SMITO);
Deputy Chairman, Minimally and Noninvasive Medicine Committee of Chinese Medical Doctor Association;
Standing Committee, Minimally Invasive Therapy Organization, Chinese Anti-Cancer Association (CMITO);
Deputy Chairman, Interventional therapy Committee, Chinese Chapter of the InternationalHepato-Pancreato-Biliary Association;
Vice Chairman, Liver Cancer Committee & Pancreatic cancer committee, Shanghai Association of Integrative Medicine;
Committee Member, Shanghai Anti-Cancer Association & Asian Conference on Tumor Ablation Association (ACTA)

In 2011, got second prize of Shanghai Scientific and Technological Award; second prize of MOE Technological Progress Award; In 2012, obtained the first prize of Chinese Association of Integrative Medicine; In 2012, got Meiji Life Science Award; In 2016, got First prize of Shanghai Scientific and Technological Award; Elected Shanghai Hundred Talents Program; Got more than 10 research programs as PI from the NIH / NCI-R01, U19 Project, the National Natural Science Foundation of China(3 projects). Funded more than 18 million RMB. Published more than 95 papers in Gastroenterology, Oncogene, Mol Oncol, Brit J Cancer, Eur J Cancer, Cancer, etc.; Cited: 1500 times, H-index: 23; Approved patent: 2 items; Participated in 16 clinical researches (PI).

Research focus:
Drug-resistant study in liver and pancreatic cancer and the minimally invasive therapy strategies：
1. Functions of Na+/K+ ATPase in Hepatic carcinoma and the relating drug investigation;
2. The inflammatory tumor microenvironment in liver and pancreatic cancer;
3. Clinical study of minimally invasive therapy.

Editorial Board
Terms of Appointment: September 2018 - August 2020;  September 2020 - August 2022;  September 2022 - August 2024